Circassia is a specialty pharmaceutical company focused on respiratory disease. Our commercial organization promotes our innovative asthma management products directly to specialist physicians in a number of key markets, and we market the chronic obstructive pulmonary disease (COPD) products Tudorza® and Duaklir® in the United States. Recently, we significantly expanded our commercial platform in China, launching our own direct sales team. We are working to expand our portfolio further through in-licensing, partnering or acquisition, and recently we acquired the commercial rights to the ventilator-compatible nitric oxide product LungFit PH* in the US and China.
Our asthma management products
Our market-leading NIOX® products are used by specialists around the world to aid asthma diagnosis and management. We sell NIOX® direct in the United States, United Kingdom, China, Germany and Italy. Our NIOX® products are also supplied in many other countries through our international network of partners.
Our COPD products
In the United States we have the commercial rights to the COPD products Tudorza® and Duaklir®, which we promote through our dedicated sales force.
Our LungFit PH partnership
In early 2019, we acquired the exclusive commercial rights to ventilator-compatible nitric oxide product LungFit PH in the US and China from BeyondAir Inc. BeyondAir plans to submit the product for approval in the United States in Q1 2020 for use in the treatment of hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn.
Circassia was established in 2006, and in March 2014 we completed an initial public offering on the London Stock Exchange. In June 2015, we completed the acquisition of NIOX® as part of our strategy to independently commercialize our products and broaden our portfolio, and in April 2017 we established our commercial collaboration with AstraZeneca in the United States for COPD products Tudorza® and Duaklir®. In January 2019, we acquired the commercial rights to LungFit PH in the US and China, and in February 2019 we completed the move of the Company’s shares to AIM where they are quoted under CIR.